<?xml version="1.0" encoding="UTF-8"?><xmi:XMI xmlns:cas="http:///uima/cas.ecore" xmlns:xmi="http://www.omg.org/XMI" xmlns:type="http:///org/apache/uima/trials/type.ecore" xmlns:tcas="http:///uima/tcas.ecore" xmi:version="2.0">
    <cas:NULL xmi:id="0"/>
    <tcas:DocumentAnnotation xmi:id="1" sofa="6" begin="0" end="1841" language="x-unspecified"/>
    <type:ORR xmi:id="13" sofa="6" begin="894" end="897"/>
    <type:ORR xmi:id="17" sofa="6" begin="978" end="981"/>
    <type:ORR xmi:id="29" sofa="6" begin="1280" end="1283"/>
    <type:ORR xmi:id="33" sofa="6" begin="1359" end="1362"/>
    <type:ORR xmi:id="37" sofa="6" begin="1463" end="1466"/>
    <type:ORR xmi:id="41" sofa="6" begin="1535" end="1538"/>
    <type:PFSMean xmi:id="21" sofa="6" begin="1134" end="1146"/>
    <type:OSMean xmi:id="25" sofa="6" begin="1151" end="1161"/>
    <cas:Sofa xmi:id="6" sofaNum="1" sofaID="_InitialView" mimeType="text" sofaString="BACKGROUND: The objective was to demonstrate feasibility and therapeutic efficacy&#13;&#10;of routine clinical use of the bendamustine/rituximab combination in&#13;&#10;lymphoproliferative diseases.&#13;&#10;PATIENTS AND METHODS: Data were collected retrospectively from 71 patients&#13;&#10;treated with bendamustine/rituximab combination in Tyrol/Austria. Toxicities,&#13;&#10;therapeutic response, and survival outcome in the various lymphoma entities were &#13;&#10;analyzed.&#13;&#10;RESULTS: There was considerable hematotoxicity, with neutropenia and&#13;&#10;thrombocytopenia of grade 3 or 4 in 33% and 18%, respectively. Interestingly,&#13;&#10;severe infection of grade 3 or 4 was observed in a remarkable percentage of&#13;&#10;patients with aggressive lymphoma and CLL (21% and 28%, respectively) but not in &#13;&#10;indolent lymphoma (p = 0.027). Overall, the therapeutic efficacy of&#13;&#10;bendamustine/rituximab was encouraging. In CLL, an overall response rate (ORR) of&#13;&#10;65% was achieved. Notably, in the seven previously untreated CLL patients, ORR&#13;&#10;was 86%. The therapy was effective across all FISH-cytogenetic subgroups, except &#13;&#10;for the five patients harboring 17p deletion with unfavorable prognosis (PFS 2.7 &#13;&#10;months, OS 9.3 months). In indolent lymphoma (n = 25), the bendamustine-rituximab&#13;&#10;combination induced a remarkable therapeutic effect (ORR 96%, median PFS and OS&#13;&#10;not reached). In aggressive lymphoma (n = 20), ORR was 50%; in International&#13;&#10;Prognostic Index high-risk patients (4 or 5 risk factors, n = 10), ORR was only&#13;&#10;20%, significantly inferior than in low/intermediate risk patients (ORR 70%; p = &#13;&#10;0.025).&#13;&#10;CONCLUSIONS: In the routine setting aside clinical studies,&#13;&#10;bendamustine/rituximab therapy resulted in marked clinical responses, especially &#13;&#10;in CLL and indolent lymphoma. In aggressive lymphoma, the combination of&#13;&#10;bendamustine and rituximab was effective in favorable risk patients."/>
    <cas:View sofa="6" members="1 13 17 29 33 37 41 21 25"/>
</xmi:XMI>
